Coexisting Prolactinoma and Primary Aldosteronism: Is There a Pathophysiological Link?
暂无分享,去创建一个
F. Beuschlein | M. Bidlingmaier | J. Schopohl | L. Geyer | M. Theodoropoulou | M. Treitl | F. Veglio | P. Mulatero | M. Reincke | E. Fischer | J. Burrello | T. Williams | A. Riester | A. Dietz | T. A. Williams
[1] A. Melck,et al. Secondary hypertension due to concomitant aldosterone-producing adenoma and parathyroid adenoma. , 2015, American journal of hypertension.
[2] S. Ito,et al. Aldosterone suppression on contralateral adrenal during adrenal vein sampling does not predict blood pressure response after adrenalectomy. , 2014, The Journal of clinical endocrinology and metabolism.
[3] T. Strom,et al. Genetic Spectrum and Clinical Correlates of Somatic Mutations in Aldosterone-Producing Adenoma , 2014, Hypertension.
[4] P. Stewart,et al. Extensive experience in the management of macroprolactinomas , 2014, Clinical endocrinology.
[5] D. Maiter,et al. Therapy of endocrine disease: the challenges in managing giant prolactinomas. , 2014, European journal of endocrinology.
[6] M. Reiser,et al. Age below 40 or a recently proposed clinical prediction score cannot bypass adrenal venous sampling in primary aldosteronism. , 2014, The Journal of clinical endocrinology and metabolism.
[7] Y. Yuzawa,et al. Unmasked renal impairment and prolonged hyperkalemia after unilateral adrenalectomy for primary aldosteronism coexisting with primary hyperparathyroidism: report of a case , 2013, Surgery Today.
[8] F. Veglio,et al. Long-term cardio- and cerebrovascular events in patients with primary aldosteronism. , 2013, The Journal of clinical endocrinology and metabolism.
[9] F. Casanueva,et al. Sirt1 inhibits the transcription factor CREB to regulate pituitary growth hormone synthesis , 2013, The FASEB Journal.
[10] H. Wallaschofski,et al. Prevalence of Primary Aldosteronism in Patient’s Cohorts and in Population-based Studies – A Review of the Current Literature , 2011, Hormone and Metabolic Research.
[11] M. Pelizzo,et al. Primary Hyperparathyroidism With Concurrent Primary Aldosteronism , 2011, Hypertension.
[12] A. Colao,et al. Medical treatment of prolactinomas , 2011, Nature Reviews Endocrinology.
[13] M. Yavropoulou,et al. The renin‐angiotensin‐aldosterone axis in patients with tumoral hyperprolactinemia , 2011, Clinical endocrinology.
[14] A. Hoffman,et al. Diagnosis and treatment of hyperprolactinemia: an Endocrine Society clinical practice guideline. , 2011, The Journal of clinical endocrinology and metabolism.
[15] M. Kawano,et al. A possible new syndrome with double endocrine tumors in association with an unprecedented type of familial heart-hand syndrome: a case report , 2010, Journal of medical case reports.
[16] A. Sapino,et al. Teratocarcinoma-Derived Growth Factor-1 Is Upregulated in Aldosterone-Producing Adenomas and Increases Aldosterone Secretion and Inhibits Apoptosis In Vitro , 2010, Hypertension.
[17] Alberto Fernández,et al. Prevalence of pituitary adenomas: a community‐based, cross‐sectional study in Banbury (Oxfordshire, UK) , 2010, Clinical endocrinology.
[18] P. Souverein,et al. Estimated age- and sex-specific incidence and prevalence of dopamine agonist-treated hyperprolactinemia. , 2009, The Journal of clinical endocrinology and metabolism.
[19] F. Veglio,et al. Differential diagnosis of primary aldosteronism subtypes , 2009, Current hypertension reports.
[20] R. Holle,et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism. , 2009, The Journal of clinical endocrinology and metabolism.
[21] W. Young,et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. , 2008, The Journal of clinical endocrinology and metabolism.
[22] J. Chudek,et al. Multiple Endocrine Neoplasia type 1. , 2008, European journal of internal medicine.
[23] T. Dinan,et al. Prolactin and dopamine: What is the connection? A Review Article , 2008, Journal of psychopharmacology.
[24] V. A. Villar,et al. Reactive Oxygen Species–Dependent Hypertension in Dopamine D2 Receptor–Deficient Mice , 2007, Hypertension.
[25] A. Beckers,et al. High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium. , 2006, The Journal of clinical endocrinology and metabolism.
[26] J. Romijn,et al. Malignant prolactinoma: case report and review of the literature. , 2006, European journal of endocrinology.
[27] M. Molitch. Medication-induced hyperprolactinemia. , 2005, Mayo Clinic proceedings.
[28] M. Molitch,et al. Guidelines for the diagnosis and treatment of hyperprolactinemia. , 1999, The Journal of reproductive medicine.
[29] P. Kelly,et al. Differential expression of prolactin receptor (PRLR) in normal and tumorous adrenal tissues: separation of cellular endocrine compartments by laser capture microdissection (LCM). , 1998, Endocrine research.
[30] A. Gutierrez-Hartmann,et al. A 26-Amino Acid Insertion Domain Defines a Functional Transcription Switch Motif in Pit-1β* , 1996, The Journal of Biological Chemistry.
[31] P. Kelly,et al. Functional aspects of the effect of prolactin (PRL) on adrenal steroidogenesis and distribution of the PRL receptor in the human adrenal gland. , 1996, The Journal of clinical endocrinology and metabolism.
[32] A. Mcneilly,et al. Twenty-four hour patterns of prolactin secretion during lactation and the relationship to suckling and the resumption of fertility in breast-feeding women. , 1996, Human reproduction.
[33] K. Kovacs,et al. Aldosterone-secreting adrenal adenoma as part of multiple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for polymorphic chromosome 11 deoxyribonucleic acid markers, including the MEN1 locus. , 1992, The Journal of clinical endocrinology and metabolism.
[34] M. Yamakado,et al. A patient with a prolactinoma associated with an aldosterone producing adrenal adenoma: differences in dopaminergic regulation of PRL and aldosterone secretion. , 1992, Endocrinologia japonica.
[35] J. Douglas,et al. Modulation of tissue responsiveness to angiotensin-II in hyperprolactinemic subjects. , 1990, The Journal of clinical endocrinology and metabolism.
[36] J. Funder. Target tissue specificity of mineralocorticoids , 1990, Trends in Endocrinology & Metabolism.
[37] E. Gould,et al. Pituitary prolactinoma, pancreatic glucagonomas, and aldosterone-producing adrenal cortical adenoma: a suggested variant of multiple endocrine neoplasia type I. , 1987, Human pathology.
[38] G. Benker,et al. [Clinicopathologic conference. Prolactinoma and hyperaldosteronism in a 55-year-old male: variant of multiple endocrine adenomatosis (MEA) type I?]. , 1987, Medizinische Klinik.
[39] J. Cabane,et al. Pituitary prolactinoma, adrenal aldosterone-producing adenomas, gastric schwannoma and colonic polyadenomas: a possible variant of multiple endocrine neoplasia (MEN) type I. , 1982, Acta endocrinologica.
[40] J. Funder,et al. Mineralocorticoid receptors in rat anterior pituitary: toward a redefinition of "mineralocorticoid hormone". , 1981, Endocrinology.
[41] C. Gomez-Sanchez,et al. Evidence against prolactin stimulation of aldosterone in normal human subjects and patients with primary aldosteronism, including a patient with primary aldosteronism and a prolactin-producing pituitary microadenoma. , 1977, The Journal of clinical endocrinology and metabolism.
[42] G. Albertin,et al. Journal of Clinical Endocrinology and Metabolism Printed in U.S.A. Copyright © 1997 by The Endocrine Society Endothelin-1 Stimulates Steroid Secretion of Human , 2022 .